Equillium (EQ) Other financing activities (2020 - 2026)
Equillium (EQ) posted quarterly Other financing activities of $448000.0 for Q1 2026, up 1078.95% year-over-year from $38000.0 in Q1 2025, and up 101.71% quarter-over-quarter from -$26.3 million in Q4 2025.
Analysis
Equillium (EQ) Other financing activities (2020 - 2026) Analysis & Trends
Equillium (EQ) has reported Other financing activities for 7 consecutive years, with $448000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 1078.95% year-over-year to $448000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 7386.67% YoY), while the FY2025 annual figure was $1.8 million, up 45800.0% from the prior year.
- Other financing activities improved to $448000.0 in Q1 2026 per EQ's latest filing, from -$26.3 million in the prior quarter.
- Across five years, Other financing activities topped out at $28.1 million in Q3 2025 and bottomed at -$26.3 million in Q4 2025.
- Historically, Other financing activities has averaged $335571.4 across 5 years, with a median of $73000.0 in 2022.
- Annual changes were most pronounced in 2025 — Other financing activities plunged 30080.46% — and 2026, when it surged 1078.95%.
- Equillium's Other financing activities stood at $73000.0 in 2022, then increased by 8.22% to $79000.0 in 2023, then tumbled by 210.13% to -$87000.0 in 2024, then slumped by 30080.46% to -$26.3 million in 2025, then jumped by 101.71% to $448000.0 in 2026.
- Business Quant data shows EQ's Other financing activities at $448000.0 in Q1 2026, -$26.3 million in Q4 2025, and $28.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100,000.00 |
| Mar 31, 2026 | 34.90 Mn |
| Dec 31, 2025 | -184,000.00 |
| Sep 30, 2025 | 28.06 Mn |
| Jun 30, 2025 | -15,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Dec 31, 2024 | -87,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Dec 31, 2021 | -29.01 Mn |
| Jun 30, 2021 | -51,000.00 |
| Mar 31, 2021 | 29.96 Mn |
| Dec 31, 2020 | 60,000.00 |